| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Veradermics, Incorporated$93.08
+2.13 (+2.34%)
D 34Pipeline Score Richly Valued Pharma · Clinical
Market Cap
4.25 B
EPS
-
P/E Ratio
-
Value Trade
55.83 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
20.93 M
Operating CF
-21.17 M
Total Assets
397.36 M
Total Liabilities
6.72 M
Equity
390.64 M
D/E Ratio
12,345
-1.34 %
Week
35.4 %
1 Month
109.53 %
3 Month
198.88 %
6 Month
198.88 %
5 Year
198.88 %
All Time
Cash Data
Cash Position
390.80 M
Monthly Burn
7.06 M
Runway
54.4 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
60.19 K
52 Week Range
32 - 117.71
% held by Insiders
25.42 %
% held by Institutions
52.12 %
Enterprise Value
3.85 B
Total Shares
37.37 M
Short %
12.05 %
Float Shares
19.62 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D34
Pipeline Score $165M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 45%
Small Cap (rank 499 of 905)
Percentile RankVeradermics, Incorporated faces pipeline headwinds (34/100), with $254M risk-adjusted pipeline value, led by VDPHL01 in Androgenetic Alopecia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VDPHL01 Small molecule | Androgenetic Alopecia (AGA) | Phase 3 | NCT07146022 | 54% | $207M | RECRUITING | 552 | STALLED | B (67) | Jan 1, 2028 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MANE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Veradermics, Incorporated (MANE) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MANE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MANE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MANE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MANE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MANE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MANEVeradermics to Present at Upcoming June 2026 Investor Conferences
Veradermics, a biopharmaceutical company focused on pattern hair loss, will present at investor conferences in June 2026. Their lead product, VDPHL01, is in Phase 3 development and aims to be the first FDA-approved oral non-hormonal treatment for this condition. The company highlights the significant market demand for effective treatments for pattern hair loss.
Read more →MANEVeradermics to Present at Upcoming June Investor Conferences
Veradermics is set to present at several investor conferences in June. The details of the presentations and the conferences have not been disclosed in the article. This announcement indicates the company's ongoing engagement with investors and the market.
Read more →MANEVeradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research
Veradermics has announced a poster presentation regarding the topline results from their Phase 2/3 study of VDPHL01. This presentation will take place at the 2026 World Congress for Hair Research. The announcement highlights the company's ongoing research efforts in hair restoration treatments.
Read more →MANEVeradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
Veradermics has announced two poster presentations regarding VDPHL01 at the upcoming 2026 Music City SCALE Symposium. The details of the presentations and their implications for the research community remain unspecified in the announcement.
Read more →MANEVeradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics has released its financial results for the first quarter of 2026, highlighting recent corporate and clinical advancements. The report outlines the company's financial performance and any significant developments in their clinical programs. Further details on specific achievements or challenges were not disclosed in the article.
Read more →MANEVeradermics Announces Pricing of Upsized Public Offering and Private Placement
Veradermics has announced the pricing of an upsized public offering of 3,843,790 shares at $100.00 each, aiming to raise approximately $384.4 million. Additionally, the company is conducting a private placement of 300,000 pre-funded warrants for about $30 million. Both offerings are expected to close on May 1, 2026, subject to customary conditions.
Read more →MANEVeradermics Announces Launch of Public Offering
Veradermics has announced a proposed public offering of 3,350,000 shares of common stock, along with pre-funded warrants. The offering is part of their strategy to raise capital for developing therapeutics for pattern hair loss. The company is also entering into a private placement with certain investors. The completion of the offering is contingent on market conditions.
Read more →MANEVeradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
Veradermics, Incorporated has reported positive topline results from its Phase 2/3 clinical trial of VDPHL01, an oral minoxidil formulation. The trial involved over 500 males with mild-to-moderate pattern hair loss. The results indicate early and robust hair growth, showcasing the potential of this innovative treatment.
Read more →MANEVeradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics is set to hold a conference call to discuss the topline results from their Phase 2/3 study of VDPHL01, a treatment for males experiencing mild-to-moderate pattern hair loss. This call aims to provide insights into the study's findings and implications for future developments.
Read more →MANEVeradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
Veradermics has reported its financial results for the fourth quarter and full year of 2025. The company also highlighted recent corporate and clinical updates. However, specific details regarding financial performance and clinical developments were not disclosed in the article.
Read more →MANEVeradermics to Participate in Upcoming March Investor Conferences
Veradermics, a late clinical-stage biopharmaceutical company, will participate in two investor conferences in March 2023. CEO Reid Waldman will engage in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami. The company is focused on developing treatments for aesthetic and dermatological conditions, including its lead program for pattern hair loss.
Read more →MANEVeradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
Veradermics has completed enrollment in its second Phase 3 clinical trial for VDPHL01, an oral treatment for male pattern hair loss. This milestone includes over 1,000 participants across both trials. VDPHL01 aims to enhance hair restoration while minimizing cardiac risks. The company is advancing towards its first NDA filing for an oral treatment in nearly three decades.
Read more →MANEVeradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
Veradermics, a late clinical-stage biopharmaceutical company, has successfully closed its upsized initial public offering, selling 17,339,294 shares at $17.00 each. The offering generated approximately $294.8 million in gross proceeds. The shares are now trading on the New York Stock Exchange under the ticker symbol 'MANE'.
Read more →MANEVeradermics Announces Pricing of Upsized Initial Public Offering
Veradermics, a late clinical-stage biopharmaceutical company, has announced the pricing of its upsized initial public offering of 15,077,647 shares at $17.00 each, aiming to raise approximately $256.3 million. The shares are set to begin trading on the NYSE on February 4, 2026, under the ticker 'MANE'. The offering is contingent on customary closing conditions.
Read more →Competitive Position
How MANE ranks across every disease it competes inCompetitive Position is a premium feature
See how MANE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial